EP1007042A4 - Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction - Google Patents

Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Info

Publication number
EP1007042A4
EP1007042A4 EP98929059A EP98929059A EP1007042A4 EP 1007042 A4 EP1007042 A4 EP 1007042A4 EP 98929059 A EP98929059 A EP 98929059A EP 98929059 A EP98929059 A EP 98929059A EP 1007042 A4 EP1007042 A4 EP 1007042A4
Authority
EP
European Patent Office
Prior art keywords
modulation
signal transduction
protein tyrosine
cellular signal
heteroaryl compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98929059A
Other languages
German (de)
French (fr)
Other versions
EP1007042A1 (en
Inventor
Peng Cho Tang
Gerald Mcmahon
John Y Ramphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of EP1007042A1 publication Critical patent/EP1007042A1/en
Publication of EP1007042A4 publication Critical patent/EP1007042A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP98929059A 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction Withdrawn EP1007042A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4956097P 1997-06-13 1997-06-13
US49560P 1997-06-13
PCT/US1998/012333 WO1998056376A1 (en) 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Publications (2)

Publication Number Publication Date
EP1007042A1 EP1007042A1 (en) 2000-06-14
EP1007042A4 true EP1007042A4 (en) 2001-07-04

Family

ID=21960475

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98929059A Withdrawn EP1007042A4 (en) 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Country Status (5)

Country Link
EP (1) EP1007042A4 (en)
JP (1) JP2002512628A (en)
AU (1) AU8071698A (en)
CA (1) CA2293400A1 (en)
WO (1) WO1998056376A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
EP1066257A2 (en) * 1998-03-26 2001-01-10 Sugen, Inc. Heterocylic classes of compounds for the modulating tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
EA005032B1 (en) 1998-05-29 2004-10-28 Сьюджен, Инк. Pyrrole substituted 2-indolinone (variants), pharmaceutical composition (variants), method for modulation of catalytic activity method for treating and preventing a protein kinase related disorders in an organism
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
DE60023920T2 (en) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphate mimetics and methods of treatment with phosphatase inhibitors HIBITORS
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
SI1255752T1 (en) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc Pyrrole substituted 2-indolinone protein kinase inhibitors
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
PE20030008A1 (en) 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
ATE348828T1 (en) 2001-10-19 2007-01-15 Transtech Pharma Inc BETA-CARBOLINE DERIVATIVES AS PTP INHIBITORS
BR0214553A (en) * 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compounds, process of liquid phase preparation of compounds and pharmaceutical compositions
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
AR047894A1 (en) 2004-02-25 2006-03-01 Wyeth Corp THIOPHEN DERIVATIVES AS INHIBITORS OF PROTEIN THYROSINE PHOSPHATASE 1B (PTPASA 1B); METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY PTPASA 1B
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
KR102598895B1 (en) * 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 2,5-Disubstituted 3-methyl pyrazine and 2,5,6-trisubstituted 3-methyl pyrazine as allosteric SHP2 inhibitors
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
MX2019008696A (en) * 2017-01-23 2019-09-13 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors.
MX2019008695A (en) 2017-01-23 2019-09-11 Revolution Medicines Inc Bicyclic compounds as allosteric shp2 inhibitors.
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
PE20211246A1 (en) 2017-10-11 2021-07-13 Hoffmann La Roche CYCLING COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS
MX2020003579A (en) 2017-10-12 2020-07-22 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors.
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
BR112020009757A2 (en) 2017-12-15 2020-11-03 Revolution Medicines, Inc. polycyclic compounds as allosteric inhibitors of shp2
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
CN113302193A (en) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 Bicyclic pyrrolotriazolone compounds and methods of use thereof
MX2023003273A (en) 2020-09-21 2023-04-26 Landos Biopharma Inc Nlrx1 ligands.
CN120004879B (en) * 2025-02-14 2026-04-07 中国药科大学 A class of compounds containing a thioether skeleton and their application in the preparation of phosphoglycerate dehydrogenase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602851A1 (en) * 1992-12-10 1994-06-22 Zeneca Limited Quinazoline derivatives
WO1997003069A1 (en) * 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602851A1 (en) * 1992-12-10 1994-06-22 Zeneca Limited Quinazoline derivatives
WO1997003069A1 (en) * 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Foerderung der Chemischen Wissenschaften, FRANKFURT/MAIN, DE; XP002166113, Database accession no. 4752105 (BRN) *
IZV. AKAD. NAUK SSSR SER. KHIM., vol. 6, 1990, pages 1392 - 1397 *
LAGORCE JF: "Synthèse et activité antithyroïdienne de dérivés du triazole", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY - CHIMIA THERAPEUTICA, vol. 27, no. 4, 1992, pages 359 - 368, XP002166110 *
See also references of WO9856376A1 *
SHAW J T ET AL: "The preparation of some 2,6-diaminopy", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, January 1980 (1980-01-01), pages 11 - 16, XP002166112 *
THORNBER C W ET AL: "A three component cyclisation of 2-cyanamido-4,6-dimethyl pyrimidines with aldehydes and amines", SYNTHESIS, no. 3, March 1983 (1983-03-01), pages 222 - 223, XP002166111 *

Also Published As

Publication number Publication date
JP2002512628A (en) 2002-04-23
WO1998056376A1 (en) 1998-12-17
CA2293400A1 (en) 1998-12-17
AU8071698A (en) 1998-12-30
EP1007042A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
EP1007042A4 (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
AU2804597A (en) Synthesis of fluorophore-labeled dna
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU1529997A (en) Substituted histidine inhibitors of protein farnesyltransferase
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU8586298A (en) Designed protein pores as components for biosensors
AU3443997A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
PL339738A1 (en) Novel lactamic inhibitors of metaloproteinases
AU2713699A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU1381499A (en) Cell-permeable protein inhibitors of calpain
ZA983065B (en) Inhibitors of protein farnesyltranferase
DE69826878D1 (en) RECODING OF DECODED SIGNALS
DE60040524D1 (en) INTEIN-MEDIATED LIGATION OF EXPRESSED PROTEINS
AU1599299A (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators
AU5131699A (en) Cryogranulation of activated protein c
AU2766999A (en) Synthesis of chiral beta-amino acids
AU6275098A (en) Novel h-rev 107-like protein
AU4684099A (en) Oligonucleotides for enhanced modulation of protein kinase expression
AU1621400A (en) Novel phosphodiesterase interacting proteins
EP1232247A4 (en) Modulation of signal transduction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 403/12 A, 7C 07D 409/14 B, 7A 61K 31/495 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010523

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010816